NCT01953692View on ClinicalTrials.gov

A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013/KEYNOTE-013)

PHASE1CompletedINTERVENTIONAL

Enrollment

197

Participants

Timeline

Start Date

November 22, 2013

Primary Completion Date

June 26, 2020

Study Completion Date

June 26, 2020

Conditions

Myelodysplastic SyndromeMultiple MyelomaHodgkin LymphomaNon-Hodgkin LymphomaDiffuse Large B-Cell LymphomaFollicular LymphomaPrimary Mediastinal B-Cell Lymphoma

Interventions

BIOLOGICAL

Pembrolizumab

IV infusion

DRUG

Lenalidomide 20 mg

oral capsule

DRUG

Lenalidomide 25 mg

oral capsule

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT01953692 - A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013/KEYNOTE-013) | Biotech Hunter | Biotech Hunter